On October 1, Canadian Space Agency (CSA) astronaut Joshua Kutyrk is scheduled to launch from Cape Canaveral, Florida, taking along some cutting-edge Canadian technology. Space living presents unique challenges due to the human body’s inability to adapt to low gravity, leading to various health issues for astronauts. Among the concerns is the risk of developing dangerous blood clots, a critical focus for NASA in ensuring astronaut safety aboard the space station.
Extensive research has been conducted over the years to understand the impact of prolonged space travel on the human body, including the formation of blood clots. To address this risk, NASA sought innovative ways to assess and manage potential health issues in space. In response, they collaborated with Vancouver-based Response Biomedical to utilize their technology.
One key instrument of interest to NASA is capable of measuring D-dimer, a residual protein fragment in the blood following a clot. Referred to as Acute Care Testing in Space (ACTIS), this device, derived from Response Biomedical’s RAMP technology, enables quick and efficient blood tests onboard. Beyond clot detection, these devices can also detect heart attack indicators and screen for various infections like COVID-19 and RSV.
The portable and rapid nature of the blood test, providing results within minutes, enhances medical support for astronauts in space. This technology not only benefits space missions but also holds significance for healthcare in remote terrestrial communities, where timely and accurate testing is crucial.
CEO Taso Tsonis emphasized the global impact of their Canadian-developed platform, emphasizing its use on the International Space Station while highlighting the ongoing commitment to advancing healthcare testing on Earth. The potential success of ACTIS in space opens doors for its application in future human space exploration missions, aligning with NASA’s ambitions for lunar and Martian exploration.
The selection of ACTIS for the ISS mission signifies a significant achievement for Canada, showcasing the nation’s technological prowess and contribution to space innovation. This milestone reflects the enduring value and adaptability of Canadian technology, marking a notable accomplishment for Response Biomedical and the Canadian space industry.